Ged Ridgway’s Post

Changes in #brainstructure and more precisely the #microstructure is essential in any #neuromodulation therapy. Using world leading measures of #neurodegeneration like CDM, combined with pioneering method from world class collaborators at Fondazione Santa Lucia (Giacomo Koch), Harvard Medical School & Mass General Brigham (Emiliano Santarnecchi), you produce some amazing work and pave the way to really helping #alzheimer patients around the world. A huge thank you to all the authors. We are proud of our partnership here and look forward to continuing to support this intervention right through to regulatory approval. 😊 🇮🇹 🇬🇧 🇺🇸 Our new paper "Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study" is now available online via the link below. https://lnkd.in/gDAP56w4 Sinaptica Therapeutics #rTMS #innovation #neurodegeneration #alzheimersdisease #cortex #precunus #MRI #Diffusion #Dementia #noninvasive #neuroplasticity

Go further than macrostructure. Cortical Disarray Measurement (CDM) was able to find changes in grey matter #microstructure using #SinapticaTherapeutics neuromodulatory therapy. Check our our paper below. #neurodegeneration #alzheimersdiease #diffusionMRI

According to The Health Management Academy's latest newsletter, service line growth decisions guide investment strategy. “Leaders reported prioritizing cardiovascular, oncology, and neurology service lines. Therefore their investment decisions are tied to innovations supporting these service lines. All of these investments are important as these service lines are seeing patients needing higher acuity care compared to five years ago. To keep cost-per-case under control, many are pursuing innovations focused on earlier detection and preventative care.” What innovations do you want to implement? Let us know in the comments. #defydisease #healthcareinnovation #defydefeatrepeat #AI #cancercare #cancermoonshot

Congratulations to EPIFOCUS on their recent Phase I #STTR award. Their project, entitled "Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus", is an interdisciplinary effort to develop more effective clinical management of #StatusEpilepticus (SE) in collaboration with the Barrow Neurological Institute.  Currently, there are no #biomarkers to rapidly, quantitatively and objectively predict the effectiveness of an intervention to disrupt SE, guide subsequent medication choices, or predict neurologic outcome. The project aims to develop and validate such biomarkers, which could help shorten the duration of SE, reduce morbidity and mortality after SE, as well as serve as surrogate endpoints in clinical trials for new treatments of SE. #Epilepsy 

Breaking news 🧠 Eli Lilly and Company Kisunla™ is FDA approved for the treatment of early symptomatic Alzheimer's disease, offering patients a way to slow the disease's progression, and improve their quality of life. "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis," said Anne White, and President of Lilly Neuroscience International Medical Imaging companies play a critical role in the analysis of brain scans for Neurodegenerative disease markers. Aside from the big names, younger companies like Qynapse, Cortechs.ai, icometrix, Oxford Brain Diagnostics Ltd, Darmiyan , Vistim Labs and others work tirelessly to support the positive patient impact of drugs like Kisunla! #earlydetection #medicalimaging #artificialintelligence

Can a digital cognitive assessment detect the presence of amyloid status and preclinical Alzheimer’s Disease? Fresh from the Alzheimer’s Association International Conference (#AAIC), Cognivue, Inc. presented a poster titled: Detection of Amyloid Status and Preclinical Alzheimer’s Disease Using Cognivue Clarity®, An Adaptive Psychophysics Computerized Cognitive Battery in The Bio-Hermes Study. Main Takeaways: 1. Cognitive Clarity—a 10-minute self-administered digital cognitive assessment based on an FDA cleared technology—is able to distinguish between: ➡️Cognitively normal/amyloid negative vs Preclinical AD ➡️Cognitively normal, MCI and mild dementia regardless of amyloid status 2. The composite score of 3 subtests has moderate correlations with amyloid PET, pTau217 and APS and can distinguish between cognitively normal/amyloid negative, Preclinical AD, and MCI-AD groups 3. Cognivue Clarity can be used to establish whether there is: ➡️Cognitive impairment, regardless of underlying pathology ➡️Likelihood of presence of amyloid, even in the cognitively normal population View the poster here: https://bit.ly/4cnoA5Y Data from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation. #aaic24 #biohermes #alzheimersdisease #amyloid #preclinical #mildcognitiveimpairment #MCI #milddementia #cognitiveassessment #biohermes #earlydetection #cognivue

🔬 Join Fortrea for an upcoming webinar featuring pharma experts and patient organizations to discuss patient-centric approaches in #neurodegenerative disorder research. Expert speakers will explore advancements in precision medicine, including fluid and imaging biomarkers for patient identification, stratification, and treatment response monitoring. The session will highlight how integrating patient and caregiver input into clinical trials can enhance effectiveness and outcomes. Learn about the role of biomarkers and the necessity of extensive patient participation. ➡️ Register here + more info: https://buff.ly/4ehYO5v #AlzheimersDisease #ParkinsonsDisease #PrecisionMedicine #PatientCentricity #PatientRecruitment #TherapeuticAreas #ClinicalTrialEndpoints #NeurodegenerativeDisorders #ImagingBiomarkers #DigitalBiomarkers

📣 Breaking News in Alzheimer's Treatment Eli Lilly and Company's Kisunla (donanemab) has been approved for treating early symptomatic Alzheimer's Disease! This new treatment option offers patients a way to slow the disease's progression, and improve their quality of life. 💉 Kisunla has shown remarkable phase III trial results, reducing cognitive and functional decline by up to 35% in its Phase 3 trial, and boasts a convenient monthly infusion schedule. It is the only drug on the market that supports stopping treatment once amyloid plaques are removed, though it has a higher rate of Amyloid Related Imaging Abnormalities (ARIA). 🧠 At Cortechs.ai, we are at the forefront of ARIA management with our 510k-pending NeuroQuant ARIA technology. NeuroQuant ARIA is an advanced AI-driven solution designed to assist healthcare professionals in detecting and monitoring ARIA with precision. Our NeuroQuant ARIA reports deliver comprehensive and detailed analysis, helping doctors make informed decisions and mitigate potential risks associated with ARIA. #AI #AlzheimersDisease #AD #ARIA #radiology

What are the headwinds, tailwinds, and opportunities in neuromodulation and neurodegenerative disease? Catch the full #LSIUSA24 panel recording, now live on our website and YouTube channel. This discussion features leading innovators and strategics exploring the complexities of the brain, addressing the challenges, and identifying opportunities in advancing neuromodulation and combating neurodegenerative diseases. Tune in to, “The Decade of Brain Health: Headwinds, Tailwinds, and Opportunities in Neuromodulation and Neurodegenerative Disease” to hear from this incredible group of panelists: • Mike Labbe (Moderator) — Velentium • Kip Roberts — Medtronic • Ken Mariash — Sinaptica Therapeutics • Ana Maiques — Neuroelectrics • Brent Vaughan — Cognito Therapeutics, Inc. Want to see more content like this? Registration and applications to present are open for LSI Europe ‘24 this September 16th - 20th at the Penha Longa Resort, in Portugal. Secure your spot today to ensure you get the best rate.

MS International Federation (MSIF) Atlas of #Multiplesclerosis. Highlighting global patient populations, it is estimated that over 2.9 million individuals worldwide are living with Multiple Sclerosis #MS. Quantum BioPharma is in the process of developing a promising drug candidate, called Lucid-MS. In Multiple Sclerosis (MS), damage to the myelin sheath is primarily believed to result from an autoimmune attack. However, the idea that Multiple Sclerosis is an underlying neurodegenerative disorder could be valid, and is separate from the autoimmune component. Most approved therapies on the market today focus on the auto immune component. Novel therapies are needed to tackle the neurodegenerative aspect of the disease. Both the autoimmune attack and the degenerative process may lead to damage to the myelin sheath and ultimately to demyelination of axons. As the myelin sheath significantly enhances the efficiency, speed, and accuracy of communication between neurons, disruptions in the myelin sheath can lead to neurological disorders like multiple sclerosis. The degradation in signal transmission between neurons produces symptoms such as loss of motor control, impaired sensory perception and decline in various cognitive functions. Quantum BioPharma Lucid MS Team Lakshmi P. Kotra & Dr. Andrzej Chruscinski Ashwini Joshi and others has played a crucial role in overseeing the development of this drug, with a strong focus on advancing the science behind it. https://lnkd.in/eEWp-XAz